J Assist Reprod Genet (2012) 29:821–827
DOI 10.1007/s10815-012-9782-2
GENETICS
Preimplantation genetic diagnosis for chromosome
rearrangements – one blastomere biopsy versus two
blastomere biopsy
D. Brodie & C. E. Beyer & E. Osborne & V. Kralevski &
S. Rasi & T. Osianlis
Received: 26 February 2012 / Accepted: 24 April 2012 / Published online: 12 May 2012
# Springer Science+Business Media, LLC 2012
Abstract
Purpose Preimplantation Genetic Diagnosis (PGD) has proven to be a useful reproductive option for carriers of some
chromosome rearrangements. The data presented in this study
compares the impact of one versus two blastomere biopsy on
the likelihood of achieving a PGD result, as well as the effect
on subsequent embryo development and clinical outcomes.
Methods IVF-PGD couples had either one or two blastomeres biopsied from all embryos with ≥7 blastomeres on
day 3 post oocyte collection. These blastomeres were
assessed for the specific chromosome rearrangement using
Fluorescent In-situ Hybridisation (FISH). Further embryo
development was monitored on days 4 and 5. Clinical outcomes were assessed retrospectively.
Results The data shows that statistically more embryos
achieved a PGD result following two blastomere biopsy, compared with one blastomere biopsy (92 % versus 88 %, respectively). Furthermore it was found that embryo development and
clinical outcomes were similar between the two biopsy groups.
Conclusions Based on this analysis it appears that the biopsy of two blastomeres from embryos with ≥7 blastomeres on
day 3 is a valid and successful approach for couples presenting for IVF-PGD for a chromosome rearrangement.
Keywords In vitro Fertilisation (IVF) . Preimplantation
Genetic Diagnosis (PGD) . Fluorescent In Situ Hybridisation
(FISH) . Embryo biopsy . Translocation
Capsule The number of blastomeres biopsied from an embryo must be
a careful balance between obtaining highly accuracy PGD results
without compromising embryo quality and clinical outcomes.
D. Brodie (*) : C. E. Beyer : E. Osborne : V. Kralevski : S. Rasi :
T. Osianlis
Monash IVF,
1/252 Clayton Rd,
Clayton, VIC 3168, Australia
e-mail:
[email protected]
Introduction
Carriers of balanced chromosome rearrangements (e.g. translocations or inversions) are at increased risk of producing
chromosomally unbalanced offspring or suffering recurrent
pregnancy loss as a result of meiotic malsegregation of the
chromosomes involved in the chromosome rearrangement. Preimplantation Genetic Diagnosis (PGD) is a reproductive option
available to carriers of balanced chromosome rearrangements.
PGD provides the opportunity to distinguish between normal/
balanced versus unbalanced embryos prior to implantation,
thereby increasing a couple’s chance of a viable pregnancy.
In 2010, Harper et al [7] estimated that approximately 90 %
of in vitro fertilisation (IVF) clinics perform embryo biopsy
and PGD on day 3 of the embryos’ development, when the
embryo is typically composed of 6–8 blastomere cells. Despite this, there is currently no consensus between clinics as to
how many blastomeres should be removed from the embryo
for genetic analysis. Some clinics advocate the removal of a
single blastomere [4,6], while others recommend that two
blastomeres be biopsied in order to obtain a conclusive PGD
result [1,9,13]. Given that embryo biopsy is an invasive procedure, it has long been recognised that this procedure could
affect the subsequent growth and development of the embryo
[3]. The European Society for Human Reproduction and
Embryology (ESHRE) PGD consortium guidelines (2010)
state that while the removal of more than one blastomere can
have detrimental affects on clinical outcomes, the removal of
two blastomeres may be required in some cases in order to
improve the diagnostic accuracy of the PGD test. To help
maintain both embryo viability and diagnostic accuracy,
ESHRE recommend that two blastomeres only be taken from
embryos that consist of six or more blastomeres on day 3 [8].
While the removal of multiple blastomeres is not thought to
affect the processes of compaction and blastulation, it has
been hypothesised that this process may interfere with
822
blastomere polarisation and the allocation of blastomeres to
the trophectoderm and inner cell mass [13]. This raises the
question, does more harm than good come from two blastomere biopsy compared to one blastomere biopsy? Any decision on this issue must be based on the need to obtain highly
accurate and reliable PGD results without significantly compromising embryo quality and clinical outcomes.
Our clinic operates a large IVF program and offers PGD
as a clinical procedure to both internal patients and patients
cycling at referring IVF units throughout Australia and New
Zealand. Here we present data from 170 IVF-PGD cycles
for chromosome rearrangements that were performed at our
clinic and referring clinics from June 2004 to September
2009. The first aim of this study was to investigate whether
the number of blastomeres biopsied from a day 3 embryo
influenced the percentage of embryos with a conclusive
PGD result. The second aim was to determine whether there
was any significant difference between one blastomere biopsy compared with two blastomere biopsy in relation to
ongoing embryo development and patient clinical outcomes.
Materials and methods
Study design
This study involved an analysis of 898 embryos from 170 PGD
cycles for 114 couples having PGD for a chromosome rearrangement at our clinic from June 2004 to September 2009.
Between June 2004 and September 2008 all couples presenting
for chromosome rearrangement testing had two blastomeres
biopsied from their embryos, providing that the embryo had ≥7
blastomeres on day 3 post oocyte collection. In 2008, a preliminary analysis showed that 92 % of embryos that achieved a
PGD result following two blastomere biopsy could have
achieved a conclusive PGD result from the first biopsied
blastomere alone. Based on these findings, and the assumption
that the removal of only one blastomere would significantly
improve clinical outcomes, single blastomere biopsy commenced from September 2008. For this study, only embryos
≥7 blastomeres on day 3 were included in the data sets (despite
the fact that embryos ≥5 blastomeres were considered suitable
for day 3 biopsy), as these embryos were of suitable size for
either one or two blastomeres to be removed. This allowed for
a more accurate comparison between the one and two blastomere biopsy groups.
J Assist Reprod Genet (2012) 29:821–827
designed and developed for each couple using probes commercially available from Vysis Inc (Abbott Molecular, Illinois,
America) and Poseidon (Kreatech, Amsterdam, The
Netherlands). The FISH probes were specifically selected to
enable all segregates of the chromosomal rearrangement to be
distinguished.
FISH conditions were initially optimised on peripheral
blood lymphocytes from each partner. The expected binding
location of each probe was confirmed by metaphase analysis. A measurement of uncertainty was performed to ensure
that the FISH probes were providing reliable results with a
sensitivity of ideally ≥95 % [12]. The optimised test was
validated on single blastomeres from embryos donated to
research and training, once the embryos had been allowed to
succumb. Once an accurate test had been developed, couples were able to commence an IVF-PGD cycle.
Ovarian stimulation and embryo development
Each couple underwent controlled ovarian hyperstimulation
to generate multiple oocytes. Oocyte retrieval occurred 36–
38 h post human chorionic gonadotrophin (hCG) administration (either 250 mg of recombinant [rhCG] Ovidrel (Merck
Serono, Australia) or 10 000 IU of urinary [uhCG] Pregnyl
(Organon, Australia)). The oocytes were inseminated using
either standard IVF or intracytoplasmic sperm injection
(ICSI). Oocytes destined for ICSI were assessed for maturity,
with only those at metaphase II considered suitable for insemination. The success of insemination was assessed 18 h post
insemination with normal fertilisation confirmed by the presence of two pronuclei. Between day 3 to day 5 post insemination, the embryo development was evaluated on a daily
basis and the developmental stage recorded. Embryo development stages were recorded as ‘the number of blastomeres’,
morula, early blastocyst, blastocyst, expanding blastocyst,
hatching blastocyst or hatched blastocyst. For the purpose of
this paper, these embryo development stages were grouped
into three categories, namely (1) the number of blastomeres
present for cleavage stage embryo, (2) morula, defined as the
presence of compaction and (3) blastocyst, defined as the
presence of a blastocoel cavity and inner cell mass.
Genetically and morphologically suitable embryos were
transferred to the uterus on either day 4 (providing they had
continued to develop post biopsy) or day 5 (providing they
had developed to the compacting stage or beyond). Luteal
support consisted of either Crinone (Merck Serono, Australia)
or progesterone pessaries (Orion, Australia).
PGD test development
Embryo biopsy and PGD
Before commencing an IVF-PGD cycle, all couples underwent
genetic counselling and test development to determine if PGD
was possible for their particular chromosome rearrangement. A
specific fluorescence in-situ hybridisation (FISH) test was
Embryos were de-compacted in Ca2+/Mg2+ free biopsy media (COOK Medical, Australia). A hole was drilled in the
zona pellucida using a ZILOS laser (Hamilton Thorne
J Assist Reprod Genet (2012) 29:821–827
Research, Massachusetts, America) and one or two blastomeres gently aspirated for PGD analysis. The embryo
was washed in blastocyst culture media (COOK Medical,
Australia) and transferred into a fresh drop of media for
ongoing culture.
Single blastomeres were fixed using Carnoy’s fixative as
per the method described by Velilla et al. [14]. Fixed slides
were pre-treated (if required) using the protocol recommended by Vysis Inc. The relevant probe mix (1 μl) was applied
to the fixed blastomeres and a 10 mm round coverslip added
and sealed with paraffin film. Slides were hybridised in a
Hybrite (Vysis Inc) using the optimised FISH conditions.
Post hybridisation washes were performed and 4.5 μl of
DAPI counterstain (Vysis Inc) added. Nuclei were analysed
independently by two PGD scientists using an Olympus
BX51 fluorescent microscope (Olympus Optical CO. LTD,
Tokyo, Japan).
Embryos were considered normal/balanced for the autosomal chromosomes when two signals were present for each
of the probes used. Embryos were considered normal/balanced for the sex chromosomes when two signals were
present for X chromosome probes and no signals were
present for Y chromosome probes, or when one signal was
present for each of the X and Y chromosome probes. Extra
or missing signals were considered to represent an unbalanced chromosome complement which renders the embryo
not suitable for transfer. Two signals were considered to
represent two homologue chromosomes when the signals
were at least two domains apart, a domain being the diameter of one signal [10]. Signals were considered split if the
signals were less than two domains apart and hence counted
as one signal [10]. For embryos that underwent biopsy of
two blastomeres, the embryo was considered mosaic if one
blastomere was defined as normal/balanced and the other
blastomere as unbalanced. The overall result for these embryos was recorded as unbalanced and not suitable for
transfer. Two blastomeres were considered to be concordant
if both blastomeres gave the same result of either normal/
balanced or unbalanced.
Throughout the study period, all technical procedures
involving embryo biopsy and FISH were rigorously
monitored by quality control programs of International
Organisation for Standardisation (ISO 9001:2000) and
National Association of Testing Authorities, Australia
(NATA). Other than the change in the number of blastomeres biopsied from an embryo, all aspects of embryo
biopsy and FISH techniques remained unchanged during
the study period.
Outcome measures
PGD results were measured in terms of ‘diagnostic efficiency’, which was defined as the number of embryos with a
823
result per number of embryos biopsied. This outcome measure was further assessed in terms of the percentage of
embryos with a result from the first biopsied blastomere
alone. For the one blastomere biopsy group this was defined
as the number of embryos with a result per the number of
embryos biopsied, while for the two blastomere biopsy
group, this was defined as the number of embryos with a
result from the first biopsied blastomere alone per the number of embryos biopsied. The two blastomere biopsy group
was also assessed for concordance which was defined as the
number of embryos that achieved the same result from both
blastomeres per the number of embryos with a result from
two blastomeres.
Embryos were grouped according to the expected developmental milestones on days 3, 4 and 5. The developmental
milestones were as follows: day 3 (number of blastomeres),
day 4 (morula) and day 5 (any of the blastocyst stages). The
number of embryos at each developmental stage on days 3,
4 and 5 was compared between the one and two blastomere
biopsy groups.
Clinical outcomes were measured as ‘implantation rate’
(number of fetal heart beats/total number of embryos transferred), ‘pregnancy rate per PGD cycle’ (number of viable
clinical pregnancies/number of initiated cycles), ‘pregnancy
rate per transfer’ (number of viable clinical pregnancies/
number of embryo transfers), ‘miscarriage rate’ (number of
fetal heart beats lost/number of fetal heart beats), ‘live birth
rate’ (number of delivery events/number of embryo transfer
procedures).
Clinical pregnancies were defined as the presence on
ultrasound of a viable gestational sac (with fetal heart beat)
at 6–7 weeks gestation.
Statistical analysis
χ2, Fisher’s exact and t-tests were used for statistical comparisons between the one and two blastomere biopsy
groups. A p-value ≤0.05 was considered statistically
significant.
Results
Patient characteristics and clinical outcomes
The patient characteristics for each group are outlined in
Table 1. There was no significant difference between the one
blastomere and the two blastomere biopsy groups in terms
of the number of PGD cycles assessed, number of couples,
mean maternal age, mean number of IVF cycles with oocyte
retrieval, mean number of PGD cycles and the total number
of embryos biopsied. The one blastomere biopsy group had
significantly more embryos biopsied per PGD cycle when
824
J Assist Reprod Genet (2012) 29:821–827
Table 1 Patient characteristics
and clinical outcomes
a
Suitability for transfer was
based on an assessment of embryo morphology in conjunction
with a genetic diagnosis of normal/balanced
Number of blastomeres
biopsied
Number of PGD cycles assessed (number of couples)
Mean maternal age
Mean number of IVF cycles with oocyte retrieval
Mean number of PGD cycles
Number of embryos biopsied (mean per PGD cycle)
Number of normal/balanced embryos (%)
Number of embryos suitable for transfer (%)a
Number of PGD cycles with transfer (%)
Mean number of normal/balanced embryos available per transfer
Mean number of normal/balanced embryos transferred per cycle
Implantation rate (%)
Pregnancy rate per PGD cycle (%)
Pregnancy rate per transfer (%)
Miscarriage rate (%)
Live birth rate (%)
compared to the two blastomere biopsy group (6.25 versus
4.7 respectively, p00.0027).
Diagnostic efficiency and PGD results
Between June 2004 and September 2009, 898 day 3 embryos
≥7 blastomeres in size were biopsied. One blastomere was
biopsied from 400/898 (45 %) embryos and two blastomeres
were biopsied from the remaining 498/898 (55 %) embryos.
Over the study period, testing was performed for a total of 71
different chromosome rearrangements (64 reciprocal translocations, 5 Robertsonian translocations and 2 pericentric inversions). Overall, significantly more embryos in the two
blastomere biopsy group achieved a PGD result compared with
the one blastomere biopsy group (92 % versus 88 % respectively, p00.0269) (Fig. 1). However, when assessing the first
biopsied blastomere alone (i.e. comparing the one blastomere
biopsy group with the first biopsied blastomere from the two
100%
% of embryos
80%
n=351
*
n=459
n=424
*
One blastomere
Two blastomeres
* p=0.0269
60%
88%
92%
85%
One
blastomere
Two
blastomeres
64 (48)
34.33
4.67
1.36
400 (6.25)
110 (28)
95 (86)
43 (67.2)
2.2
1.5
11 (21.2)
11 (17.2)
11 (25.6)
1 (9.1)
10 (23.3)
106 (66)
33.96
3.25
1.61
498 (4.70)
109 (22)
100 (92)
60 (56.6)
1.66
0.9
20 (25)
20 (18.9)
20 (33.3)
2 (10)
16 (26.6)
p- value
(0.0027)
0.0001
0.0001
blastomere biopsy group) there was no significant difference
between the two biopsy groups in terms of the percentage of
embryos with a conclusive result (88 % one blastomere biopsy
versus 85 % two blastomere biopsy) (Fig. 1).
Analysis of the two blastomere biopsy group revealed
that 378/498 (76 %) of embryos obtained a result from both
biopsied blastomeres, with 321/378 (85 %) of these embryos achieving a concordant result from both blastomeres (i.e.
both blastomeres were normal/balanced or both blastomeres
were unbalanced). A non-concordant result was obtained for
the remaining 57/378 (15 %) of embryos.
To further assess the level of concordance we have performed a small reanalysis of embryos that underwent PGD for
a chromosome rearrangement. The reanalysis involved ten
embryos that were originally diagnosed as unbalanced following PGD. Upon reanalysis of these embryos, nine embryos
were confirmed to be unbalanced for the chromosome rearrangement. One embryo was classified as normal/balanced
following reanalysis. This particular embryo originally had
two blastomeres biopsied, one of which gave a normal/balanced result and the other an unbalanced result. Due to the
presence of the unbalanced blastomere this embryo was classified as unbalanced and not suitable for transfer.
40%
Embryo development
20%
0%
PGD result
PGD result from first
biopsied blastomere
alone
Fig. 1 Comparison of the percentage of embryos (≥7 blastomeres on
day 3) that achieved a PGD result for one blastomere versus two
blastomere biopsy groups
There was no significant difference in embryo development
between the one blastomere and two blastomere biopsy
groups on days 3 and 4. There was also no difference
between the groups on day 5 in terms of the number of
embryos reaching the blastocyst stage (Table 2). Further
J Assist Reprod Genet (2012) 29:821–827
825
Table 2 Comparisons between the one blastomere and two blastomere
biopsy groups for the number of embryos at the blastocyst stage
on day 5
One
Two
blastomere blastomeres
Number of embryos on day 5
Number of embryos at the blastocyst stage (%)
Number of normal/balanced embryos (%)
Number of unbalanced embryos (%)
213
96 (45)
54 (56)
42 (44)
225
91 (40)
47 (52)
44 (48)
assessment also showed that there was no significant difference between the one blastomere and two blastomere biopsy
groups in terms of the number of normal/balanced or the
number of unbalanced embryos at the blastocyst stage on
day 5 (Table 2).
Clinical outcomes
Clinical outcomes are summarised in Table 1. There was no
significant difference between the two biopsy groups in
terms of number of normal/balanced embryos, number of
normal/balanced embryos suitable for transfer (based on
embryo morphology) or number of cycles with a transfer.
Transfer of morphologically and genetically suitable embryos occurred on day 4 for 15 (25%) patients from the two
blastomere biopsy group while all remaining transfers were
performed on day 5. The one blastomere biopsy group had a
significantly higher number of normal/balanced embryos
available per transfer compared to the two blastomere biopsy group (2.2 versus 1.66 respectively, p00.0001). Subsequently, the one blastomere biopsy group had a significantly
higher number of normal/balanced embryos transferred per
cycle compared to the two blastomere biopsy group (1.5
versus 0.9 respectively, p00.0001). Despite this, there was
no significant difference in implantation rate, pregnancy
rate, miscarriage rate or live birth rate between the two
biopsy groups.
Discussion
Since the introduction of embryo biopsy and PGD, the
methodology used in the laboratory has been closely monitored to ensure an ongoing quality of service. The number
of blastomeres biopsied from a day 3 embryo requires
careful consideration and must be a compromise between
achieving high diagnostic efficiency while minimising any
detrimental affects on subsequent embryo development and
clinical outcomes. The data presented in this paper indicates
that the number of blastomeres biopsied from a day 3
embryo is associated with the percentage of embryos with
a conclusive PGD result. Significantly more embryos
achieved a conclusive PGD result following two blastomere
biopsy compared to one blastomere biopsy (92 % and 88 %
respectively). In regards to the two blastomere biopsy
group, some instances arose where a second blastomere
was required to clarify a difficult analysis from the first
biopsied blastomere. In other instances the availability of a
second blastomere may have allowed for the detection of
mosaicism which may in turn have prevented an embryo
with a mosaic unbalanced chromosome complement from
being transferred.
A study published by Michiels et al. [9] also compared
the biopsy of one versus two blastomeres and explored the
accuracy and reliability of PGD results. They similarly
found that significantly more embryos achieved a PGD
result following two blastomere biopsy when compared to
embryos that had one blastomere biopsied. They did not
however, assess ongoing embryo development following
biopsy. Furthermore, there was a large difference in size
between the one blastomere biopsy group which had only
118 (6.3 %) embryos biopsied compared to the two blastomere biopsy group which had 1711 (90.6 %) embryos
biopsied. An additional 59 embryos (3.1 %) had three blastomeres biopsied. This was in contrast to the current study,
where the one blastomere biopsy group had 400 (44.5 %)
embryos and the two blastomere biopsy group had 498
(55.5 %) embryos. Another difference between our study
and that of Michiels et al. [9] is that their study included data
from day 3 embryos that varied in size from five blastomeres up to compacting. They biopsied one blastomere if
the embryo contained five blastomeres on day 3, or two
blastomeres if the embryo contained ≥6 blastomeres on day
3. Our study limited the data set to the assessment of
embryos ≥7 blastomeres in size on day 3, which allowed
us to evaluate ongoing embryo development and clinical
outcomes without the one blastomere biopsy group being
skewed by the inclusion of day 3 embryos that were deemed
to be of poorer quality.
The two blastomere biopsy group was further analysed in
relation to concordance of PGD results between blastomeres. This analysis showed that 85 % of embryos had a
concordant result from both biopsied blastomeres, while the
remaining 15 % of embryos tested had a non-concordant
result (i.e. one blastomere was normal/balanced and the
other blastomere was unbalanced). One possible explanation
for a non-concordant FISH results is embryo mosaicism
which has been reported by some groups to be as high as
40–60 % [8]. Other factors that may contribute to nonconcordant results include technical errors, which may result from poor blastomere quality, FISH probe error and/or
incorrect FISH interpretation (due to overlapping signals,
spilt signals, signal bleed through and the presence of autofluorescent debris on the slide) [10]. While FISH
826
interpretation can be subjective and scoring differences can
occur, the implementation of rigorous FISH training programs and the adherence to specific FISH scoring criteria
are used to mitigate these effects. Furthermore, the possibility of FISH probe error should be minimised during the test
development process, given that a measurement of uncertainty is performed to confirm low probe error rates (i.e.
≤5 %) prior to the test being offered clinically. Given that all
possible measures had been taken to minimise technical
errors, one could assume that a significant proportion of
non-concordant results are in fact due to mosaicism. Our
results indicate that the biopsy of two blastomeres increases
the ability to detect mosaicism and aids in avoiding the
transfer of a mosaic unbalanced embryo.
It was interesting to note that the one blastomere biopsy
group had a significantly higher mean number of embryos
available per transfer than the two blastomere biopsy group
(2.2 versus 1.66 respectively). While this may in part be due to
the fact that the one blastomere biopsy group had a significantly higher number of embryos biopsied per PGD cycle, it is
also possible that the one blastomere biopsy group contained
embryos which would have been identified as mosaic unbalanced if two blastomeres had been biopsied. Sandalinas et al.
[11] and Emiliani et al. [5] reported that mosaic embryos are
capable of developing to the blastocyst stage. Based on this, it
could be hypothesised that a mosaic unbalanced embryo
incorrectly diagnosed as “normal/balanced” following one
blastomere biopsy has the potential to reach the blastocyst
stage and be transferred. Depending on the chromosomal
imbalance involved and the proportion of unbalanced blastomeres, this may result in implantation failure, miscarriage, or
the birth of a chromosomally abnormal child. This could help
explain why the one blastomere biopsy group did not have a
higher pregnancy rate than the two blastomere biopsy group,
despite having more embryos available for transfer.
The current study has shown that there is no significant
difference in embryo development on days 3, 4 and 5
between the one blastomere and two blastomere biopsy
groups. Furthermore, our data indicates that there is no
significant difference in clinical outcomes following the
removal of one versus two blastomeres. While these findings support previous data reported by Van de Velde et al.
[13] and Michiels et al. [9], they are in contrast to studies
performed by other groups [4,6]. The laboratory of
Goossens et al. [6] and De Vos et al. [4] reported that the
removal of more than one blastomere from a day 3 embryo
has a detrimental affect on developmental potential and day
5 embryo quality, and subsequently on clinical outcomes.
This difference in findings may be attributed to different
biopsy criteria being used by different laboratories. In this
study, we only considered embryos ≥7 blastomeres in size
suitable for two blastomere biopsy. This contrasts to Goossens et al. [6] and De Vos et al. [4] who biopsied one or two
J Assist Reprod Genet (2012) 29:821–827
blastomeres from embryos ≥6 blastomeres in size. It is
possible that embryos with fewer blastomeres on day 3
respond more poorly to the biopsy of two blastomeres than
embryos of greater size, presumably due to a larger percentage of their cellular mass being removed. It is also interesting to note that De Vos et al. [4] included embryos
consisting of 5 blastomeres in their one blastomere biopsy
data set, despite the fact that these embryos were not considered suitable for two blastomere biopsy and were therefore not included in the two blastomere biopsy group. By
only including these poorer quality embryos in the one
blastomere biopsy group and not the two blastomere biopsy
group, the data becomes biased and it is not possible to
perform an appropriate comparison between the two groups.
By applying a day 3 embryo size restriction (embryos ≥7
blastomeres in size) to our data we have been able to make a
true comparison between the two data sets.
Another area of difference between the current study and
the studies performed by Goossens et al. [6] and De Vos et
al. [4] was the embryo culture media that was used. We have
previously shown that the type of embryo culture media
used in the laboratory can have a significant impact on
embryo development and clinical outcomes [2]. Furthermore, our previous data has demonstrated that biopsied
embryos are more susceptible to suboptimal culture conditions than non biopsied embryos [2]. It is possible that subtle
variations in culture media between laboratories could therefore impact on the embryo’s ability to withstand the biopsy
of two blastomeres. Based on this, it is advisable that each
laboratory considering two blastomere biopsy validate the
process in house to ensure that their culture system is
capable of supporting two blastomere biopsy. Our laboratory has seen very little difference in embryo development and
clinical outcomes between the two biopsy groups which
suggests that our culture system has been optimised to the
level required for either one or two blastomere biopsy.
To conclude, the results of the current study indicate that
a conclusive PGD result is more likely to be achieved
following two blastomere biopsy compared with one blastomere biopsy. Furthermore, the biopsy of two blastomeres
allows for increased confidence in the PGD result and an
increased ability to detect mosaicism. Given that the removal of two blastomeres does not affect embryo development
or patient clinical outcomes, it appears that two blastomere
biopsy is a valid and successful approach for couples with a
chromosome rearrangement presenting for IVF-PGD.
Acknowledgments The authors wish to thank the following IVF
clinics who participate in transport PGD through Monash IVF, for
kindly agreeing to provide requested data on embryo development
and clinical outcomes: Concept Fertility Centre, Hollywood Fertility
Centre, Fertility Associates, Fertility Plus, Fertility Specialists of Western Australia, Monash IVF, Next Generation Fertility, Pivet and
Repromed.
J Assist Reprod Genet (2012) 29:821–827
References
1. Baart EB, Van Opstal D, Los FJ, Fauser BCJM, Martini E. Fluorescence in situ hybridization analysis of two blastomeres from day
3 frozen-thawed embryos followed by analysis of the remaining
embryo on day 5. Hum Reprod. 2004;19:685–93.
2. Beyer CE, Osianlis T, Boekel K, Osborne E, Rombauts L, Catt J,
Kralevski V, Aali BS, Gras L. Preimplantation genetic screening
outcomes are associated with culture conditions. Hum Reprod.
2009;24:1212–20.
3. Cohen J, Wells D, Munne S. Removal of 2 cells from cleavage
stage embryos is likely to reduce the efficacy of chromosomal tests
that are used to enhance implantation rates. Fertil Steril.
2007;87:496–503.
4. De Vos A, Staessen C, De Rycke M, Verpoest W, Haentjens P,
Devroey P, Liebaers I, Van de Velde H. Impact of cleavage-stage
embryo biopsy in view of PGD on human blastocyst implantation:
a prospective cohort of single embryo transfers. Hum Reprod.
2009;24:2988–96.
5. Emiliani S, Gonzalez-Merino E, Van den Bergh M, Delneste D,
Englert Y, Abramowicz M. Correlation between fluorescence insitu hybridization analyses and in-vitro development to blastocyst
stage of embryos from Robertsonian translocation (13;14) carriers.
Hum Reprod. 2002;17:2957–62.
6. Goossens V, De Rycke M, De Vos A, Staessen C, Michiels A,
Verpoest W, Van Steirteghem A, Bertrand C, Liebaers I, Devroey
P, Sermon K. Diagnostic efficiency, embryo development and
clinical outcome after the biopsy of one or two blastomeres for
preimplantation genetic diagnosis. Hum Reprod. 2007;23:481–
92.
827
7. Harper JC, Coonen E, De Rycke M, Harton G, Moutou C,
Pehlivan T, Traeger-Synodinos J, Van Rij M, Goossens V. ESHRE
PGD consortium data collection X: cycles from January to December 2007 with pregnancy follow-up to October 2008. Hum
Reprod. 2010;25:2685–707.
8. Harton GL, Magli MC, Lundin K, Montag M, Lemmen J, Harper
JC. ESHRE PGD Consortium/Embryology Special Interest Group
– best practice guidelines for polar body and embryo biopsy for
preimplanation genetic diagnosis/screening (PGD/PGS). Hum
Reprod. 2010;0:1–6.
9. Michiels A, Van Assche E, Liebaers I, Van Steirteghem A, Staessen
C. The analysis of one or two blastomeres for PGD using fluorescence in-situ hybridisatiion. Hum Reprod. 2006;21:2396–402.
10. Munne S, Marquez C, Magli C, Morton P, Morrison L. Scoring
criteria for preimplantation genetic diagnosis of numerical abnormalities for chromosomes X, Y, 13, 16, 18 and 21. Mol Hum
Reprod. 1998;4:863–70.
11. Sandalinas M, Sadowy S, Alikani M, Calderon G, Cohen J, Munne S.
Developmental ability of chromosomally abnormal human embryos
to develop to the blastocyst stage. Hum Reprod. 2001;16:1954–8.
12. The Preimplantation Genetic Diagnosis International Society (PGDIS).
Guidelines for good practice in PGD: programme requirements and
laboratory quality assurance. RBM Online. 2008;16:134–47.
13. Van de Velde H, De Vos A, Sermon K, Staessen C, De Rycke M,
Van Assche E, Lissens W, Vandervorst M, Van Ranst H, Liebaers I,
Van Steirteghem A. Embryo implantation after biopsy of one or
two cells from cleavage-stage embryos with a view to preimplantation genetic diagnosis. Prenat Diagn. 2000;20:1030–7.
14. Velilla E, Escudero T, Munne S. Blastomere fixation techniques
and risk of misdiagnosis for preimplantation genetic diagnosis of
aneuploidy. Reprod BioMed Online. 2002;4:210–7.